Latest / Quantum Potential / Chemist Brian Bachmann Charts Path to Personalized Treatment
Transcript
- 0:00We came up with a method to get DNA into these organisms.
- 0:04This microporous membrane assisted in generic transfer— so what we call that in the lab, there are conjugal lagoons ... So what that is is we have the, the DNA, the DNA that we would like to get ...
- 0:18and I thought about using that in the paper, but it seemed a little steamy— little 'Blue Lagoon' or something like that— but what what we did is we developed a way to have DNA from E. coli inserted into our target organism.
- 0:33So they, they actually literally mate.
- 0:33The E. coli mates with the micromonospora and inserts its DNA into that.
- 0:40And that's a way to get DNA in very efficiently.
- 0:42Wow.
- 0:42You mix E. coli with micromonospora, but then how do you get rid of the E. coli?
- 0:49My guest today is Brian Bachmann, Stevenson Professor of Chemistry.
- 0:53Brian Bachmann is professor of chemistry in the Vanderbilt University Department of Chemistry.
- 0:58As principal investigator at the Vanderbilt Laboratory for Biosynthetic Studies, his research is concerned with biosynthesis and discovery of natural and unnatural products.
- 1:09He pursues ways of understanding and manipulating biological systems, ranging from microbial ecologies to human biology.
- 1:29Welcome to 'Quantum Potential,' a podcast dedicated to curiosity and discovery.
- 1:34My name is Cybele Raver, and I serve as the provost of Vanderbilt University.
- 1:39As a leader in higher education and as a social scientist, I believe that we can transform higher education for the 21st century.
- 1:45At my core, I am wildly curious about other people's work, whether it's in science, the social sciences, the humanities, or the arts.
- 1:54This podcast gives us the opportunity to break open new ideas through discovery and creative expression.
- 2:07Prior to Vanderbilt, Brian was director of Chemistry at Ecopia Biosciences, where he helped build the first genome mining program for natural product discovery.
- 2:16As a professor at Vanderbilt, Brian leads a large, highly dynamic and well-funded research lab.
- 2:21He holds multiple patents for his work, and he's the founder of a startup in addition to his federally funded science.
- 2:29Brian, you've just had a major paper come out in the American Chemical Society's major journal, 'Chemical Biology.' Congratulations, and welcome.
- 2:37Thank you.
- 2:37It's so nice to be here, Cybele.
- 2:38So great.
- 2:40Really many times, uh, thank you for being here.
- 2:43Before we go deep into your work, Brian, I'd love to set the stage— just to ask a few questions, um, really simple questions, that clarify some things.
- 2:51I'm fascinated by the type of work you do, specifically around this idea of biosynthesis.
- 2:57I think when I imagine, uh, the production of drugs, I, like many people, maybe many people in this audience, think about that as chemists in massive industrial labs cranking away as part of what I imagine to be "big pharma." I don't really think about biological organisms making drugs— other than maybe penicillin, which I have only a vague understanding of as being produced by a mold.
- 3:24Really, you help me to understand that drugs are produced by biological organisms on a major scale, and for many millennia, or more than millennia—millions of years, right?
- 3:38I think more, yes.
- 3:40You mentioned that active molecules, uh, serve as the foundation of an incredibly wide array of drugs.
- 3:45You mentioned a breast cancer drug being produced by a specific species of sea sponge.
- 3:50Help me understand—why are bacteria or fungi or plants or other biological organisms so good at making therapeutics?
- 4:00Wow.
- 4:00That's a great question.
- 4:01Well, you know, many of our drugs are ... natural products or natural product-based.
- 4:07Most of our antibiotics are natural product or natural product-based.
- 4:11You know, household names like penicillin that you mentioned, erythromycin, tetracycline— those are all compounds made by soil bacteria, believe it or not, in one form or another.
- 4:22And many, many cancer drugs— you know, at least half of cancer drugs— have their origins as natural products.
- 4:28And some of the most highly prescribed drugs such as, you know, Taxol are natural products and they, they're made by plants and bacteria and fungi and all these kinds of organisms.
- 4:41So a, a natural product is synthesized inside of the organism that makes it.
- 4:47And it's made because it gives some kind of a survival benefit to that organism.
- 4:52It's evolved to have a function in that organism, and the organism produces that molecule by assembling it atom by atom inside of a cell, and it con converts what we call primary metabolites, which are things like amino acids and nucleotides and fatty acids, into natural products by multi-step, almost choreographies ... molecular choreographies that are like a production line, but they're inside of a cell.
- 5:24And when you describe that in these articles, it's clear that it's not six steps or 20 steps.
- 5:32It's thousands of steps with thousands of candidate metabolites that might be put together in different ways with different shapes and different structures.
- 5:42Yeah.
- 5:43Ultimately that, that's true.
- 5:44You know, and that, you know, to generate enough of an antibiotic, to have it be usefully isolated, an organism will have done thousands and thousands of reactions.
- 5:55Usually it takes about, you know, between 12 to maybe 100 individual steps to make a single natural product.
- 6:06But if you added all the other pieces that, of the components that they're derived from, starting with carbon dioxide, fixing that, and making sugars and those becoming carbon in these scaffolds, then it would be thousands.
- 6:17Amazing.
- 6:17And so tell me a little bit about this metaphor of "fight club." Mm-hmm This idea that actually I was wrong when I used the word millennia.
- 6:24That when I'm ... we're thinking about time and, uh, the evolution of these bacteria or these biological organisms, that they absolutely have come up with these clever means of creating these drugs.
- 6:36Yeah.
- 6:37Well, all organisms on the planet are connected, and we communicate with each other, and we are dependent upon each other and we ...
- 6:45we antagonize, we mutualize, we cooperate, we fight.
- 6:50And we are in an ecological web with every organism on the planet, one way or the other.
- 6:55You know, that's all a matter of scale.
- 6:56And we start to go down to smaller and smaller scales, and, you know, at a micro- ... microbial scale, microorganisms are competing with each other in ... on tiny, tiny scales.
- 7:07Not tiny to them, you know?
- 7:09And their, their ecosystems are like small cities with many, many players and many, many citizens ... many, many components ...
- 7:17and they're trying to find a way to succeed in those environments.
- 7:22Sometimes they're attacking one another; sometimes they're just defending their potential offspring, if you will; sometimes they're cooperating, and they're working together for a common cause.
- 7:34An interesting thing about all these natural products, like penicillin for instance—we do not know why it exists in nature.
- 7:42We have no idea what its function is in the ecology from which it's isolated.
- 7:46At least not yet.
- 7:48Other cases we do, and what we've learned is that natural products exist to facilitate inter-organism interactions.
- 7:59like fighting and defense and cooperation, often between kingdoms.
- 8:03So you might have a bacteria on an insect; the bacteria might make a natural product, an antifungal compound that protects the insect from a fungal infection.
- 8:13So you have these multiplayer interactions, and it's these molecules, these special molecules that can manipulate these complex ecosystems toward a advantage for the organism.
- 8:25It's so cool because I think increasingly in, sort of, popular understanding— whether it's because you see it on the shelves of Whole Foods or because a friend is suddenly telling you about you, you know, the microbiome— we've come to understand that we live in this complex ecology and that a complex ecology lives inside us, right?
- 8:44Yeah.
- 8:44But I don't think ... I fully understood that this complex ecology is producing all of these amazing, incredibly complex molecules to either fight or defend or communicate in the environment around us ...
- 9:00Yeah.
- 9:00... at this very micro level.
- 9:03Yeah.
- 9:03I mean, if you think about it, a disease is an ecosystem.
- 9:08When we have a bacterial infection, one of the many bacteria inside ...
- 9:10inside of us has decided that it wants to eat us, or, you know, take advantage of us one way or another.
- 9:18So there is a, there's a, a dysfunction within our microbiome, within the collection of organisms that are us and comprise us as meta organisms that we are.
- 9:28In that way ... sense, maybe it's not surprising that we have found the tools that organisms use in nature to combat one another.
- 9:35We've taken them out of context, purified them on massive scales and then used them inside of us in order to achieve a therapeutic outcome— to manipulate a complex system in a therapeutically benefit, beneficial fashion.
- 9:49And I think that's why these molecules are so privileged.
- 9:52And as drugs and cancer—from antibiotics to, you know, to nicotine and caffeine and, and illegal drugs— is because they have evolved for billions of years to have functions to manipulate complex phenomena.
- 10:06So remarkable.
- 10:07And yet you've been so clear, um, that you're on this mission to fix some of the molecules because the ways in which they function currently Haven't been as successful as we would like as treatments, right?
- 10:21You've pointed out that they're either too toxic or they're not soluble, or they degrade too quickly, they, um, can't be stored efficiently or they can't be made on ... at scale, right?
- 10:32So ...
- 10:32That's right.
- 10:33... this idea of, from my reading, at least tell me where I've got this wrong, but this idea that you've either gonna figure out how the biological organism, whether it's bacteria or fungi, how they produce the molecule.
- 10:47And then you basically figure out how to steal their IP ...
- 10:50Mm-hmm... right?
- 10:51And take the kind of complex blueprint for how to make the molecule ...
- 10:56Yes.
- 10:56... and, and reproduce it.
- 10:58Or alternately way more cool, from my perspective, was this idea that you actually harness the bacteria or the fungi by using genomic analysis and genetic manipulation as just one set of tools ...
- 11:12Yeah.
- 11:12... to actually create, you know, what seemed like sort of Frankensteinian ...
- 11:17Mm-hmm.
- 11:18... bacteria to make the drugs the way you want them to be made.
- 11:21That's right.
- 11:21I mean, I started out my career in chemical synthesis, total synthesis of natural products, the art of it.
- 11:28And I became jealous of these organisms and their ability to make these compounds in ways, you know, I would be toiling over a simple chemical reaction and trying to string them together to make these complex molecules.
- 11:38But it occurred to me, you know, that the yew tree, the Pacific yew tree, just makes Taxol by breathing in one step.
- 11:44Wow.
- 11:44Right.
- 11:44It's a beautiful thing.
- 11:45And then, and so it's a ... how does that happen?
- 11:47You know, there's these biosynthetic pathways that happen.
- 11:50So wait a minute, let's just slow down.
- 11:51Right?
- 11:52A Pacific yew tree, like ...
- 11:53Right.
- 11:54... very tall, very beautiful.
- 11:55And it's ...
- 11:57it's just exuding Taxol, a chemical compound that— remind me of what Taxol cures?
- 12:04It's a breast cancer drug.
- 12:05Okay.
- 12:05It's one of the most important drugs in treating, you know, difficult to treat breast cancer out there.
- 12:11And it, you know, it was, it's isolated from this small tree.
- 12:15It's actually a smallish shrubbish tree— difficult to grow in large quantities.
- 12:19So now when they make it, they actually make it via, um, making an advanced intermediate by cell culture of, you know.
- 12:27And then they ... then they use chemistry to finish it up because they can't isolate enough from the plant.
- 12:32And was that some genius herbalist who figured out that the Pacific yew tree could be used to tackle a human disease?
- 12:41I mean, how did that ... what was the history of that transition?
- 12:44Or do we know?
- 12:45Yeah, I'm, I'm not super familiar with the original discovery.
- 12:49I believe it was discovered by plant natural product, cool discovery people, and they would generate extracts from plants all over the world and then assay them for activity against maybe cell lines or a biological assay that they're interested in.
- 13:05And then if they're active, then perhaps purify the compounds and then determine their structure and then isolate more and study them more and more and start to develop them as pharmaceuticals.
- 13:15So remarkable.
- 13:17So in this way that you use this form of extraction, and then you know, you've, so in one example, you've taken, you know, cultures from bacteria inside caves.
- 13:28And then you've taken those cultures back to your lab and grown them on some, some medium.
- 13:35And then you're trying to break down how that weird little biological organism that's freaked out, possibly, or not that it's no longer in its cave— it's now o=in your plastic container in your refrigerator.
- 13:51You're then gonna figure out what's active in, in, its ... what it's producing.
- 13:55Right.
- 13:55And that's, that's really the, an important part of natural product discovery.
- 14:00We have become so advanced in our understanding about how life makes molecules from a genetic to a biochemical level that we can read the genome of an organism—the As, Cs and Gs and Ts.
- 14:12And from that we can predict the structure of things that they make, even if they've never been isolated before.
- 14:18It could be completely novel compounds, and we could determine great amounts of information and prediction about what they ...at least the blueprints have the potential to produce.
- 14:28However, we don't necessarily know, or we cannot predict what kind of activity they will have or if their activity would be similar to something known or superior to something known.
- 14:39And so that that early part where we predict the structures and use that to guide discovery, is called genome mining.
- 14:44And I was involved in early commercialization and development of that technology.
- 14:50But there was something missing, which was this activity component.
- 14:53Because what we found looking at genomes is that everything's interesting.
- 14:57Everything has something worthy of chasing.
- 14:59You found a million cool tools, but you're not sure what they're gonna fix.
- 15:01Right! What are we gonna isolate?
- 15:02Which, which should ... you know, the ... each organism maybe have the ability to make 20 or 30 compounds.
- 15:07Which one do we spend months isolating?
- 15:10And we would isolate them and find out, oh, it's not active.
- 15:14Complete waste of time.
- 15:15Um, so when I came to Vanderbilt, I decided to just develop a program that would let us determine what was active inside of a crude extract.
- 15:24Like, like think about vanilla extract.
- 15:26You know, what would be active inside of a crude extract before isolating it, right?
- 15:31So that we could tell before we decided to go through this really, really labor-intensive process, um, what was interesting.
- 15:37So we developed a single cell um, analytical platform, um— with a collaborator here at Vanderbilt, Jonathan Irish— to help us, uh, look at the full metabolome, which is all the metabolites inside of a crude extract, and how each component might affect cells on a single-cell basis.
- 15:54And we asked many, many questions per cell as well.
- 15:57So we could ask maybe eight to 10 questions per cell and per compound.
- 16:02And this was the bar coding?
- 16:04Yeah.
- 16:04So we use a technology called, um, cell bar coding, and that allows us to take a metabolome, and which has all the molecules in the cell, and separate them into wells.
- 16:14Then we add cells— and we can add cells from any source.
- 16:18From a pure, from a cell line, like HeLa cells, which were isolated from he Henrietta Lacks decades ago, to human cells isolated from biopsy from cancer patients at Vanderbilt.
- 16:31And then we can see how the compounds in the wells affect the cells in the wells at a very high throughput fashion, and that guides our discovery.
- 16:56It is just so phenomenal, that whole idea of, you know, bench to bedside.
- 17:00I mean, in that paper you described specifically the cells from two different patients, right?
- 17:05Mm-hmm. A female patient and a male patient, each of whom had different forms of leukemia.
- 17:11You know, from my novice "person on the street" understanding, I had no understanding that there was that level of complexity— both in the person's disease and in the metabolome of the possible cure, right?
- 17:26Yeah.
- 17:27I mean, what we learned about cancer is, one of the reasons it's so difficult is that it's not ...
- 17:29like many human complex diseases.
- 17:35It's, it's not homogenous.
- 17:37And a patient might have seven to 10 different types of melanoma inside of a melanoma, and each one of those may have different sets of mutations in them.
- 17:48So we could develop a therapeutic to kill nine-tenths of them, But if one tenths lived, then it can come back and on, it can have recurrence.
- 17:57So our thought was that if we really wanna do discovery, we have to learn how to do it on patient samples so that we can do personalized medicine.
- 18:06Their vision is to test the compounds that we discover on multiple patient samples that have been, have their diseases characterized by genetics, and to be able to see how tens of thousands of cells from a single biopsy respond to molecules that we put on them.
- 18:22It lets us see that beyond the averages, the population averages, and ferret out, you know, which subtypes are responding and which subtypes ... aren't responding.
- 18:30And does patient No. 1 respond better than patient No. 15— and well, maybe we should develop these drugs for patient 15.
- 18:37I love that from the perspective of, I think is very multivariate, it's very multidimensional, and that idea that we have distributions of the way that a person's disease is being expressed.
- 18:48But also the way that those different cell types are all interacting and interacting with the, the, the therapeutic.
- 18:55It's fascinating.
- 18:56Right?
- 18:56And if you think, again, back to our discussion on ecosystems and manipulating ecosystems.
- 19:01They're complex.
- 19:02They have many players.
- 19:03It's like trying to change the weather to change a, a microbiome or change a chemical ecology toward a direction that you want it to go.
- 19:12And it's kind of like that with treating cancer.
- 19:14You're trying to change a, a complex interaction of normal cells and healthy cells and cancerous cells, steer them in the right direction.
- 19:21So, you know, our hypothesis is that we'll take these tools that have already evolved to do that, and we'll try those.
- 19:28And it's turned out that's been successful, you know, throughout, throughout the decade.
- 19:32So fascinating.
- 19:33So did those bacteria from the caves in Sparta, Tennessee, actually deliver?
- 19:38I mean, did they do what you had hoped, or was it ultimately great on method but not necessarily great on outcome?
- 19:44Well, we found a class of compound— we chose the organism by looking at its genome, and we realized that it would make a compound that was similar to a known standard of care leukemia drug.
- 19:54But it was different.
- 19:56So we chose that as our model system to start out.
- 20:00And when we grew them up, we found that it did make that class of compound.
- 20:05And that it was a new compound.
- 20:07And the structure was only slightly different from the one that was in the clinic.
- 20:11So you might say, well, this is not going to be particularly surprising.
- 20:15But the small structural differences end up causing very great changes in how it responds patient to patient.
- 20:23Mm-hmm. In unexpected ways.
- 20:25And we think that our field may have ignored a lot of, um, natural products.
- 20:31They've been left on the cutting room floor because they've only looked at them against one cell line or, or one patient.
- 20:37And that nobody does patient samples, as far as I know, with discovery.
- 20:41So they've, they've just missed a lot and that there could be just ... huge potential for personalized medicine by reinvestigating new and known natural products.
- 20:52So cool.
- 20:53I love that about the spirit of your work, this sort of sense of pulling these sort of dusty gems from the shelves that where they've been parked for a while, and that you really want to revitalize our understanding of them.
- 21:06Um, one of them was this really great work that you've done on the micromonospora carbonacea, which sounds like an Italian food dish, I don't know?
- 21:17It's delicious.
- 21:18Yeah.
- 21:18It does not sound like a word that ever comes up in my field.
- 21:22But, um, this is a spore that is in soil?
- 21:26Yeah.
- 21:26These are soil dwelling microorganisms, micromonospora, they make two- spore ... or they make monospores, so they're called micromonospora.
- 21:34Okay.
- 21:34There's also a bispora and a tetraspora.
- 21:36Cool.
- 21:37And you know, they're, they're a bit rare in terms of soil organisms; they're not as commonly occurring, but they make this antibiotic substance that was discovered originally, The first member of this was discovered in the 1960s.
- 21:50A new member of it was discovered in the eighties and developed by Schering-Plough and to treat antibiotic-resistant infections in the nineties.
- 21:59And it was fabulously active against multiple drug-resistant infections.
- 22:04But it, they encountered a problem during clinical trials, and they decided to discontinue development.
- 22:11So it's this tragedy, like this ...
- 22:11made to stage 3 clinical trials.
- 22:15Wow.
- 22:15Mid stage 3, which is just about the finish line, and they made a decision to stop developing it.
- 22:21And now, now we're living in this post-antibiotic era.
- 22:24We need these kinds of tools desperately to counter infections.
- 22:27So we thought, well, maybe, maybe we can take our knowledge of biosynthetic pathways and, and apply it to making new analogs.
- 22:35So I would analogize it toward, you know, take ...
- 22:38We've been spending our lives taking apart watches to see how they work.
- 22:41You're very systematically dissecting them and numbering the pieces on a piece of paper.
- 22:45That's immediately the image that I had. That, or like, you know, the entire factory where you're not just figuring out how to make a steering wheel or taking the car apart to make this figure that out.
- 22:54You're like looking for the tiny bolt and the tiny lug nut.
- 22:58Exactly right.
- 22:59Super, super detailed.
- 23:01Very detailed and, and the thought is, can we take the knowledge that we've learned by taking apart pocket watches and build new devices?
- 23:08You know—the basic principles, and I think that we can do that.
- 23:12And the case with the everninomicin, that compound that is produced, is one example where we've taken that forward substantially.
- 23:21Loved it.
- 23:22I love if you would be willing to read this little section about how you take that task on.
- 23:27Okay.
- 23:28Glad to.
- 23:32"Toward our goal of identifying key everninomicin biosynthetic analogs, We performed a functional analysis of the three remaining genes to ascertain their function in biosynthetic order.
- 23:44This was accomplished first by determining the effects of everninomicin biosynthesis of replacing targeted genes with antibiotic markers using microporous membrane assisted intergeneric transfer followed by biochemical analysis.
- 24:02Break that down for those of us who don't do any of those things.
- 24:06Okay.
- 24:06Well, you know, the hard part about studying biosynthetic pathways and organisms like this is that there's no genetic system.
- 24:13So to, to edit DNA, you have to learn ... in an organism, you have to figure out how to get DNA in and out, and you have to develop tools to do that.
- 24:23So we had to develop a way to introduce, um, DNA into these organisms so that we could replace genes with other, with other genes to examine what their function are.
- 24:35And we usually replace them with an antibiotic marker so that we know that we did it.
- 24:38So we could.
- 24:40Gene X is mysterious.
- 24:41What does it do? Well, let's replace gene X with penicillin resistance, and then we can see what happens to the molecules when we remove that one machine from the assembly line.
- 24:53And so it's sort of like deleting things to find out how things work.
- 24:57We came up with a method to get DNA into these organisms, this microporous membrane assisted intergeneric transfer.
- 25:05So what we call that in the lab, there are conjugal lagoons.
- 25:11So what that is, is we have the, the DNA, the DNA that we would like to get ...
- 25:15and I, I thought about using that in the paper, but it seemed a little steamy ...
- 25:19'Blue Lagoon' or something like that.
- 25:21But what what we did is we developed a way to have DNA from E. coli inserted into our target organism.
- 25:30So they, they actually literally mate ...
- 25:30the E. coli mates with the micromonospora and inserts its DNA into that.
- 25:37And that's a way to get DNA in very efficiently.
- 25:40Wow.
- 25:40You mix E coli with micromonospora, but then how do you get rid of the E. coli?
- 25:46E. coli is ... grows so fast, it grow ... doubles very quickly, and then micromonospora doesn't.
- 25:53So we found that if we put them in these conjugal lagoons that they could ... get romantic.
- 25:58And then there are pores on the bottom—which our organism can pass through, but the E. coli cannot— of the bottom of a, of this lagoon, which they can go into a agar dish. And we can pull the lagoon off and then we can isolate just our target micromonospora.
- 26:14That is wild.
- 26:15Okay, so you have this ecology that has only the micromonospora in it.
- 26:19You introduce this completely different ...
- 26:22Mm-hmm.
- 26:22... what is E. coli?
- 26:24It's a gram-negative bacteria.
- 26:26Okay.
- 26:26Lives in our stomach.
- 26:27Yeah.
- 26:27Great. And then you figure out how after they've engaged in, in some kind of wild genetic exchange.
- 26:37Conjugation.
- 26:38Okay.
- 26:38Conjugation.
- 26:39You're able to sort 'em out and get them back into separate worlds again.
- 26:45That's right.
- 26:45And then the DNA from the E. coli has been injected into the organism of interest.
- 26:50And it can undergo recombination Just like, just like in, in, in, in mammalian cells.
- 26:56And you can replace one gene with another.
- 26:59Yeah.
- 26:59Okay.
- 27:00And did that involve specifically very precise genetic editing?
- 27:05Or are you allowing a whole raft of genetic processes to occur, and you're just capturing and describing a few of them, but there's also a ton else going on.
- 27:15It's, it's, it's a super precise, um, base pair resolution.
- 27:19So it would be just like Microsoft Word, cutting out a paragraph and inserting a new paragraph into a document.
- 27:25Amazing.
- 27:25It's very, very precise.
- 27:26This CRISPR technology does similar things in mammalian cells, you know, but it doesn't work as well in bacterial cells.
- 27:33And, and you know, maybe because it comes from bacterial cells, and bacteria already evolved to resist it ...
- 27:40Wow.
- 27:41... to some degree.
- 27:41But we've, we've not yet succeeded in getting CRISPR gene editing to work.
- 27:46When I say "we," I mean the field.
- 27:48A student in my lab worked for a year at it and couldn't get it to work.
- 27:51So we use these, these, these other methods of genetic recombination of precisely swapping genes, and that's the most efficient way that we currently know.
- 28:00Amazing.
- 28:01So you've created now EVNQ, which I imagine to be this sort of Frankensteinian ...
- 28:09Mm-hmm.
- 28:10... mutant version.
- 28:12Yeah.
- 28:13It's, it's almost a, like, um, it's a deletion, you know, mutant.
- 28:17So we deleted genes that install one, um, portion of the molecule.
- 28:24We, and we, we suspected that's what they did, And when we deleted them, we, we found analogs in the molecule lacking that one piece.
- 28:32It's got another awful name, which is dichloroisoeverninic acid, what we call DCIE.
- 28:38But it's a, it's a, it's a ring that we think is important for its biological activity.
- 28:42Uh, you know, a six ... hexagon membered ring.
- 28:45So we, we knocked that off by knocking out the genes that encode it.
- 28:49And then, um, Audrey in my lab learned how to then put it back on by using biocatalysts that she developed straight out of the organism itself.
- 29:00Which is a whole second process in this paper that I really wanted to know more about.
- 29:05So I want to get back to the DCIE rings, and I want to know whether your parents or your children or your friends, like, sit around by the fireside while you tell them tales of and incantations of the DCIE ring recombinant structures.
- 29:21Because ...
- 29:22That sounds like a magic spell, right?
- 29:23No, it really does, right?
- 29:24Like there's this fascinating it, it reminded me of German.
- 29:28Yeah, like it seems the length of the word tells you a lot about the structure of what you're talking about.
- 29:35Yeah.
- 29:36It's a descriptive term, and I can remember long chemical names and I can remember Latin names of microorganisms, but I have trouble remembering all the students in my classroom's names.
- 29:46It's much easier for me to remember these scientific names than, than it is those.
- 29:49That's totally great.
- 29:50But yeah, no, we, you know, we, we, once we, we can also take the integral things that we've deleted, and then we can express them, purify them as proteins that are, they're basically little catalysts that we can produce.
- 30:01And then we can use them just like a chemical reagent, you know, in a test tube.
- 30:06And combining synthetic analogs of that DCIE ring that have different ... different structures, we can use that to, to mate those together and make new analogs of these compounds that have never existed and have never been envisioned by nature ... contain elements that nature doesn't, doesn't use very much, like fluorine and, and unusual functionality.
- 30:31And we think that this gives us the tools that we need then to go in and start to edit the molecule to improve upon the liabilities that it showed in the clinic.
- 30:42Where did that ultimately lead with this particular journey, with this particular paper?
- 30:47Is it closer, much closer to yielding a therapeutic or a pharmaceutically functional molecule than when you started?
- 30:57I think we're at, we're at the point now where we have the tools to do the editing, and we've discovered the importance of that DCIE ring, and we've narrowed down to why it is unique and why it is required for making these compounds active.
- 31:12So now a graduate student in my lab, uh, Ben, is chasing down that lead and trying to make analogs that we think overcome the problems that we're seeing in the clinic.
- 31:24We think we're close.
- 31:25I think we're close.
- 31:43You mentioned a couple times the word aromatic, uh, and other words ...
- 31:46Mm-hmm. ... relating to esters.
- 31:48Do these rings give off a scent?
- 31:51What would I notice if I walked into your lab, right?
- 31:53This, this bacteria apparently creates the earthy smell in earth.
- 31:58They do.
- 31:58Right?
- 31:59They do.
- 32:00That smell, geosmin, it's a molecule made when it rains, and you come out and you say "It smells like rain." Well, that's made by soil bacteria that release this compound, and they're talking to each other ...
- 32:10Wow.
- 32:10... after it rains and saying, "Hey, wake up.
- 32:12It's wet!" You know.
- 32:14Um, but they are aromatic.
- 32:15Well, why are they called aromatic?
- 32:17Well, it's interesting.
- 32:18Um, I read this book a year ago called 'The Elixir,' and it's about the origins of organic chemistry.
- 32:23Okay?
- 32:23The author makes the case that the origins of organic chemistry are in the perfume industry in Paris.
- 32:30And these people were ...
- 32:31So much for incantations, and ...
- 32:34... they were starting to,... middle earth, we're going straight to us It was this.
- 32:38And they thought, they thought that good-smelling things made you healthy.
- 32:41Huh?
- 32:41So they started to distill and separate these compounds into individual components.
- 32:45And when they had them pure— like peppermint, menthol— they were able to actually determine their structures for the first time.
- 32:52And that led to modern organic chemistry.
- 32:54And many of them did smell, and the, it was the smells that led to the discovery, and they were natural products as well ...
- 32:59Mm-hmm. Oregano oil, camphor, menthol, all these things.
- 33:05And that led to the modern era of chemistry and organic chemistry as we know it.
- 33:09So everninomicin does not have a smell.
- 33:12It's too heavy, its vapor pressure is not low enough.
- 33:16Not yielding it any kind of, yeah.
- 33:18But the organism smells.
- 33:19Amazing.
- 33:20And Brian, how did you get, or what drew you to nature as the lab?
- 33:26You know, it's not a story that I think of or know when I think immediately of, yeah.
- 33:32Jealousy.
- 33:32Okay.
- 33:33Jealousy.
- 33:33You know, and, and, um, you know, being inspired by these beautiful compounds and that we were working on making chemically.
- 33:40Just the, it was sort of a big intellectual challenge and a, and a methodological challenge to make these molecules ourselves that nature had produced.
- 33:49And then thinking, well, somebody's done this before me.
- 33:53Something has done this before me.
- 33:57I need to figure out what it is doing so that I can co-opt the tools myself and do the synthesis of unnatural molecules using the tools that life has evolved.
- 34:08And is that, um, something that everybody else in your discipline completely gets behind or is it a bit renegade?
- 34:16I think it's growing.
- 34:18Um, it, you know, the, I wrote this article to try to convince people that this is a cutting-edge field that we need to invest in.
- 34:26And I'm, I, and I outlined a number of examples of people who have started to do this kind of work, where they, they either approach it from a chemical side and recruit enzymes as biocatalysts— or they approach it from a biological side, and they recruit chemistry to modify it.
- 34:41And I think, you know, using our, our own engineering skills and using our own intuition and creativity, we can expand upon the molecular diversity of that nature has created and, and, and address it.
- 34:53Because natural products are not evolved for use in humans.
- 34:57Soil bacteria doesn't make, um, antibiotics for us.
- 35:01It makes it for its own purposes.
- 35:03So, you know, they could be toxic, they could be insoluble, they could be unstable, they could just have no oral availability, lots of things.
- 35:12So we need to go in with, you know, hammer and tongs and modify the structure of these molecules to make them more appropriate for human medicine.
- 35:19And this is, I think, a key pathway forward.
- 35:22And many people stopped doing discovery of natural products for this very reason, because they thought they couldn't make changes in these molecules because they were too complex to modify.
- 35:34So they were essentially unfixable.
- 35:37It's so interesting to see in this paper the way in which you persist.
- 35:41You and your team keep trying the next thing.
- 35:44Yeah.
- 35:45It was very fascinated by the extent to which it's obviously not a sole genius pursuit, right?
- 35:52That you're working in this really amazing group, leading this amazing group.
- 35:57And I thought it would be great to hear a little bit about how you mentor students, how you include students in that exploration, and whether they ever just want to put down that cup of coffee really late at night and say, like, "We've hit a limit.
- 36:11Like, there's no, there's no more forward to go." Oh, that will never happen. Um, well, you know, my laboratory, as you mentioned in the intro, is called the Laboratory for Biosynthetic Studies.
- 36:23So, I was inspired by reading a biography of Carl Sagan, right, when I was an assistant professor and, and he named his laboratory the Laboratory for Planetary Studies.
- 36:34So I thought, oh! And I like, I like the idea of it's not the Bachmann Lab. And, and I, and I'm always, correcting my, my, my students that it's not my lab.
- 36:45It's our lab.
- 36:46And, um, you are the guys who do the work.
- 36:49You're the guys who bring the, the innovation.
- 36:53I will mentor you through this process, and I will write the grants and I'll help you write the papers.
- 36:59And, but, but really it's a collective effort, and I feel very strongly about that.
- 37:03And that's, that's the basis for the name.
- 37:05It's so clear because your name is always last on every single paper.
- 37:09Right.
- 37:10Yeah.
- 37:10That, that's, that's relatively common in chemistry.
- 37:13Um, it didn't used to be, but it it has become over the years.
- 37:15Yeah.
- 37:16But, but still, laboratories like to go by the name of their ...
- 37:19By the, yes, the name of their PI.
- 37:19... PI, their principal investigator, who does the least work on the projects.
- 37:24Well, in fact, I would probably argue with you on "least work." But I like that you're foregrounding those students.
- 37:32And do undergraduates, um, find their way to your lab, as well, or is it primarily graduate students, doctoral students, postdocs?
- 37:38I've had a number of undergraduates over the years, and they've, like, gone on to professional school and, and chemistry departments and biochemistry departments.
- 37:49as well as medical schools and ...
- 37:51Amazing... M.D./Ph.D., and you name it.
- 37:54And do they see your startup portion of your life as a person who patents, um, new intellectual property and gets things going in a private sector space?
- 38:04Well, yeah, that's a, that's a recent, uh, innovation.
- 38:07We've started this company, um, me and my collaborator at Vanderbilt, Michael Savona, started this company about a year ago last June.
- 38:15And it's been interesting and exciting to imagine a lot of the things we've talked about today and reducing them to practice to, to really industrialize what we've done in academia for many years.
- 38:26And to answer your question, I guess one of our very first employees is a former student who graduated from my lab seven or eight years ago and went into industry.
- 38:35And I was able to coax him back to help ...
- 38:37That's great.
- 38:38... take some of the stuff that he developed while in the lab into, into production and industrialize it.
- 38:44So.
- 38:45With probably a lot more control than he may have had working for someone else or, but maybe I'm just imagining that.
- 38:51Oh, I would definitely—taking a process that's just pipetting single wells and, and making it work with robots and high throughput, I think is going to be where we find out the true potential of the technology.
- 39:03Phenomenal.
- 39:03Yeah.
- 39:04You mentioned prior to our recording this, um, that you had been mentored in many other different phases of your career.
- 39:12You were mentored by Craig A. Townsend at Johns Hopkins.
- 39:16You were mentored by Professor John D. Buynak at Southern Methodist.
- 39:22And then, uh, you were inspired by, uh, your undergraduate research experience in the laboratory of Tom Hudlicky looking at biocatalytically enabled synthesis of natural inositols.
- 39:33Exactly.
- 39:34Um, so how did you get on this path to begin, Brian?
- 39:37It's really distinct and incredibly inspiring.
- 39:41The undergraduate experience was the first, and I worked for a number of years for Tomas Hudlicky, affectionately named T-Hud by students that worked for him.
- 39:49And, and he was an organic chemist, but he had this unique aspect of his program where he used an organism to do a step and a chemical reaction—a fermenter.
- 39:59And we bubbled something that was essentially toxic waste, chlorobenzene, through a, a bioreactor full of cells.
- 40:08And then it pooped out a compound that was so valuable that it was a couple thousand dollars a gram.
- 40:13Wow.
- 40:14And then we used that as a raw material to make many compounds.
- 40:17And I worked on inositols, which are a natural molecule inside of us, inside of our, our body.
- 40:22Very important.
- 40:24Um, but it occurred to me then as why can't we, why can't we use these, do more of this, these biocatalysts?
- 40:30And so I started to try to do that and I, I realized quickly that enzymes are very specific.
- 40:36They don't do ... they only do what they're evolved to do. And you try to change, make them do something different and it's very difficult.
- 40:42So I moved on to, to do synthesis and drug mechanisms and at Southern Methodist University with John Buynak.
- 40:50And, and there I did synthesis.
- 40:53I made a bunch of new antibiotics, um, scaffolds and then studied, started to study how do they work inside of a cell.
- 41:01That was totally new to me— to start dropping things into enzymes and try to understand what was happening at that point.
- 41:08It was really diff- ... really challenging and fascinating, but discovered the mechanism of how these compounds work, you know, atom by atom, you know.
- 41:14And that really got me excited so, and, and that lab was foundational in terms of touching, living things and touching enzymes.
- 41:26But I still had that goal of doing total synthesis with, with enzymes.
- 41:30So I went to work for Craig Townsend at Johns Hopkins, and that's what he did.
- 41:35He took apart watches.
- 41:36They took ... he, he's a pioneer in what was called bio-organic chemistry back then.
- 41:40We now call it chemical biology ...
- 41:41Yeah.
- 41:42... you know, taking apart these complex systems.
- 41:45And in SMU I studied how these compounds called beta-lactams, which is ... penicillin is a beta-lactam.
- 41:51And ... you know how these, these inhibitors of inhibitors of enzymes that chew up beta-lactams, how they work?
- 41:57How do, how can we keep a beta-lactam ring from busting open and making it useless?
- 42:03And then, and at Johns Hopkins, I discovered the enzyme that makes beta-lactams inside of an organism that that produces them.
- 42:10So it was the opposite of what I did at SMU.
- 42:13Wow.
- 42:13And it was called beta-lactam synthetase because it's an enzyme that makes that, that compound.
- 42:19So I got really excited about taking apart pathways down to individual enzymes and making biocatalysts.
- 42:25And so Craig Townsend was a major mentor, uh, for me and being interfacial between chemistry and biology and yeah.
- 42:33And then I had corporate mentors at Ecopia, too, so where, where we would take those blueprints and convert them into molecules and tubes.
- 42:41So that, that was a, just a super exciting and formative time.
- 42:45I, I, I never did a postdoc.
- 42:46I just came straight back to academia.
- 42:49It's very inspiring to think about that path, right?
- 42:51And the way in which you pursued several lines of inquiry that kept crossing and kept informing each other, but were also informed by being in very different places at different times.
- 43:01Yeah.
- 43:01Trying to do the thing I wanted to do in 1990 and mostly failing the entire time— and keep on trying.
- 43:06Coming, yeah.
- 43:06Coming back.
- 43:07Revise.
- 43:08Back again.
- 43:08Yeah.
- 43:09Yeah.
- 43:09Yeah.
- 43:10Amazingly persistent.
- 43:11Yeah.
- 43:11And do your students ever lose, sort of, the spirit of "keep on keeping on," of fixing the unfixable?
- 43:18Or do they ever migrate to a simpler question?
- 43:23Um, i, I, I don't know.
- 43:24I mean, so far we've been successful in getting students through the lab and, and being able to solve the problems that they're working on, whether it's a ... a novel enzyme, it's making everninomicin to, to making modifications.
- 43:40I think the students that have been working on the synthetic biology, the stuff to harness biology, to do novel chemistry are some of the bravest, and you know, because there's no guarantee of success with that.
- 43:52And I have students currently working on things that have never ever been done before, and I so admire their, their bravery in order to do that.
- 44:01But ...
- 44:01Amazing.
- 44:01... so far, I've been so pleased with, um, their ability to get it done.
- 44:05I love that.
- 44:06I love hearing that.
- 44:07I mean, as provost, I love hearing that our students are just that brave, that willing to take on a really hard challenge, and they're sort of, like, you know, "And yet we'll go for an even harder, weirder thing to try to do." I made this movie about caves that we were ... you know, they were like, "Wow, this is really exciting.
- 44:26Can you talk about this dramatic jump into a pit and rappelling down into a pit and, and how exciting and dangerous that is?" And I tried to tell them that that's nothing compared to what the students are doing in the laboratory, you know, that they are working on an atomic scale ...
- 44:39Yeah.
- 44:40... which is 10 to the minus 17th meter.
- 44:43Much, much deeper than any hole that we have ever jumped into with much more personal peril.
- 44:48And much more, much more bravery is required.
- 44:51So what you're willing to do is like show the nuclear magnetic resonance machine, because that's dramatic.
- 44:56They did not buy it.
- 44:56They did not buy that.
- 44:57Did that not signal the same visual.
- 44:59They wanted the.
- 45:00"jump in the hole." Well, I, I totally get the, uh, intellectual leap is far greater than the actual physical clambering down into the hole.
- 45:12That's totally understandable to me.
- 45:15Um, in terms of the ability to get to back to the patient, that part is just so moving.
- 45:21I think, you know, the idea that this work is not just at the cutting edge of scientific discovery, but is also at the cutting edge of saving people's lives and figuring out how to deal with really pressing societal challenges.
- 45:33Um, and so this idea that you're at that forefront of figuring out new tools that we'd never thought of or couldn't imagine, and new ways to activate pathways that have been Evolutionarily deeply informed— it's really inspiring.
- 45:48I think, you know, something that Vanderbilt fosters between having the medical school so closely innervated and with, uh, you know, the, the, the basic sciences is, you know, we get to cross-pollinate with each other.
- 46:01And we can develop empathy for our patients, and we can develop empathy for, um, problems that really, really need to be solved or very, very urgently need to be solved.
- 46:09Yeah.
- 46:10I was fortunate enough to have an M.D./Ph.D. student in my laboratory, and, and he could talk directly about case studies of things that, that we were trying to address.
- 46:18And it, it really, really impresses upon you the importance of, of keeping that sense of empathy for, for the community and for the world at large.
- 46:27And we named the company Empath Biosciences for that reason because we want to have empathy for, for unsolved problems and patients and communities and, and, and try to make progress in that area by industrializing the kinds of things we've done here— finding ways to bring science closer to solving problems that make a difference in the world.
- 46:46I mean, that's what gets us up every day and to brush our teeth with vigor— is that we hope that something that we will do is going to really make a difference.
- 46:56Thanks to our listeners for tuning in.
- 46:59Remember to stay curious, keep exploring new ideas, and we'll be back next time with another guest who's pushing the boundaries of discovery.
- 47:06Until then, I'm Cybele Raver and this is 'Quantum Potential.' The 'Quantum Potential Podcast' comes from Vanderbilt University.
- 47:23Your host is C. Cybele Raver.
- 47:26Thank you to our guest, Brian Bachmann.
- 47:26Production by Matriarch Digital Media.
- 47:32For more information about Quantum Potential, go to vanderbilt dot edu forward slash quantum potential.
- 47:42Stay curious.